News | Prostate Cancer | November 28, 2019

Radiation Therapy Effective in Patients with No Further Treatment Options

The current study from the team of nuclear radiologists in Saarland is also a small step, but one that could be decisive for future therapeutic approaches

Prof. Dr. Samer Ezziddin from Saarland University/Saarland University Hospital.

Prof. Dr. Samer Ezziddin from Saarland University/Saarland University Hospital. Photo courtesy of Thorsten Mohr/Saarland University

November 28, 2019 — Reports of new cancer treatments often raise high hopes and expectations, particularly, of course, among cancer patients and their families. But raising expectations is not something that Samer Ezziddin, M.D., professor of nuclear medicine and director of the department of nuclear medicine at Saarland University Hospital is keen to do. 'In most cases, we cannot heal the patients who take part in our therapeutic programme. Our aim is to extend life expectancy by a number of months or even years, without impairing the patients' quality of life,' explained Ezziddin. And although over the course of his career he has seen patients whose cancer has regressed completely despite extremely poor prognoses, such cases remain the exception and should be regarded as 'statistical outliers' rather than miracle cures. The battle to treat the many different varieties of cancer continues to be very challenging, involving careful but laborious work, where progress is measured in small steps and where significant advancements only become apparent after an extended period of time.

The current study from the team of nuclear radiologists in Saarland is also a small step, but one that could be decisive for future therapeutic approaches. The physicians subjected patients with advanced prostate cancer to a radiation therapy regimen that was originally developed in Heidelberg and that has now been developed further by the team in Saarland. The approach used is known as targeted radionuclide therapy. A radioactive drug injected into a patient's vein is continuously fed to the tumour site where the radioactive substance ('the radionuclide') irradiates the tumour internally, thus destroying the tumour cells.

But rather than injecting just one type of radioactive drug into the tumour, the medical research team in Saarland chose to combine two different radiopharmaceuticals each having a different irradiation path length. One of the radionuclides used was lutetium-177. This radioactive material has an effective range of 0.5 to 10 millimetres, which is the distance over which the surrounding tissue is destroyed. It is highly precise, because the radionuclide is attached to a cell-targeting molecule that only binds to receptor sites almost exclusively located on the surface of prostate tumours, leaving other healthy body cells unaffected. However, even the very short distance over which lutetium-177 is effective may be too great when treating the tiniest tumours that can form when the cancer spreads to other parts of the body. The research team led by Ezziddin therefore decided to add a second radioactive nuclide, actinium-225, to their therapy regimen. Samer Ezziddin explains the benefits as follows: 'Actinium-225 delivers excellent results; its effective path length is well down in the sub-millimetre range.'

By including actinium-225 as a therapeutic agent even the smallest of tumours, in principle even individual tumour cells, can be irradiated internally once the radioactive substance has infiltrated the cancer cell via the receptor site. 'Because the effective path length of actinium-225 is only three to four cell diameters, surrounding tissue is not destroyed,' explains Professor Ezziddin. However, previous radionuclide therapies based on actinium-225 suffered from one crucial disadvantage. The patient's salivary glands can also take up the radionuclide, causing decreased function of the glands and resulting in extreme dryness in the mouth, which can significantly reduce the patient's quality of life.

The paper just published describes the results of a pilot study that examined the effectiveness of the tandem therapy proposed by the research team from Saarland University Hospital. The study was able to demonstrate that these side effects no longer occur when lutetium and actinium are combined in a specific therapy regimen. 'Lutetium is very well tolerated for most sizes of tumour,' explains Professor Ezziddin. 'This allowed us to significantly reduce the actinium dosage level, so that our tandem therapy can be carried out with very few side effects.'

The study analysed the experiences of 20 patients aged between 57 and 88 with late-stage or end-stage metastatic prostate cancer and whose tumours no longer responded to treatment using only lutetium-177. 'The patients in our study were already heavily pre-treated. Many of them had already been told that there was little that could be done,' says Samer Ezziddin. In 14 of the 20 cases, the team observed a substantial decrease in tumour marker levels while the patients were undergoing tandem therapy. (Tumour marker concentrations indicate how much tumour mass is still in body.) It was found that after starting tandem therapy, tumour growth could be stabilized for about four and a half months (median average value) before the disease progressed, and that survival after starting tandem therapy was 11 months (median value) without any substantial reduction in the patients' quality of life.

Related Nuclear Cardiology Content:

New ASNC SPECT Imaging Guideline Addresses Advances in Myocardial Perfusion Imaging 

Dose-Lowering Practices for Nuclear Cardiology

The Past, Present and Future of PET/MRI Scanners

Recent Advances in Cardiac Nuclear Imaging Technology

VIDEO: PET vs. SPECT in Nuclear Cardiology and Recent Advances in Technology — An interview with Prem Soman, M.D.

VIDEO: Trends in Nuclear Cardiology Imaging — A discussion with David Wolinsky, M.D., director of nuclear cardiology at Cleveland Clinic Florida and past-president of the ASNC

Related Content

Radiotherapy has been used to treat cancers for more than a century and continues to be utilized in cancer treatment plans today. Since the introduction of radiotherapy, clinicians have been working tirelessly to further refine treatments to better target cancer.
Feature | Radiation Therapy | July 06, 2020 | By Yves Archambault
Everything has room for improvement, right? Right. When it comes to cancer care, it is no different.
Proton therapy has evolved, and future predictions include smaller systems, more sophisticated proton dosimetry and devices that manipulate the proton beam
Feature | Proton Therapy | July 06, 2020 | By Minesh Mehta, M.D.
The field of proton...
Researchers reviewed results of prostate biopsies on over 3,400 men who had targets identified on prostate MRI and found that the positive predictive value of the test for prostate cancer was highly variable at different sites
News | Prostate Cancer | July 01, 2020
July 1, 2020 — Prostate MRI is an emerging technology used to identify and guide treatment for...
R2* maps of healthy control participants and participants with Alzheimer disease. R2* maps are windowed between 10 and 50 sec21. Differences in iron concentration in basal ganglia are too small to allow visual separation between patients with Alzheimer disease and control participants, and iron levels strongly depend on anatomic structure and subject age. Image courtesy of Radiological Society of North America

R2* maps of healthy control participants and participants with Alzheimer disease. R2* maps are windowed between 10 and 50 sec21. Differences in iron concentration in basal ganglia are too small to allow visual separation between patients with Alzheimer disease and control participants, and iron levels strongly depend on anatomic structure and subject age. Image courtesy of Radiological Society of North America

News | Magnetic Resonance Imaging (MRI) | July 01, 2020
July 1, 2020 — Researchers using magnetic...
Cardiac MR can offer data above and beyond anatomical imaging, which is the main reason why this system was installed at Baylor Scott White Heart Hospital in Dallas. The system is a dedicated heart MRI scanner.

Cardiac MR can offer data above and beyond anatomical imaging, which is the main reason why this system was installed at Baylor Scott White Heart Hospital in Dallas. The system is a dedicated heart MRI scanner.

News | Pediatric Imaging | June 29, 2020
June 29, 2020 — A type of smart magnetic r...
Thoracic findings in a 15-year-old girl with Multisystem Inflammatory Syndrome in Children (MIS-C). (a) Chest radiograph on admission shows mild perihilar bronchial wall cuffing. (b) Chest radiograph on the third day of admission demonstrates extensive airspace opacification with a mid and lower zone predominance. (c, d) Contrast-enhanced axial CT chest of the thorax at day 3 shows areas of ground-glass opacification (GGO) and dense airspace consolidation with air bronchograms. (c) This conformed to a mosai

Thoracic findings in a 15-year-old girl with Multisystem Inflammatory Syndrome in Children (MIS-C). (a) Chest radiograph on admission shows mild perihilar bronchial wall cuffing. (b) Chest radiograph on the third day of admission demonstrates extensive airspace opacification with a mid and lower zone predominance. (c, d) Contrast-enhanced axial CT chest of the thorax at day 3 shows areas of ground-glass opacification (GGO) and dense airspace consolidation with air bronchograms. (c) This conformed to a mosaic pattern with a bronchocentric distribution to the GGO (white arrow, d) involving both central and peripheral lung parenchyma with pleural effusions (black small arrow, d). image courtesy of Radiological Society of North America

News | Coronavirus (COVID-19) | June 26, 2020
June 26, 2020 — In recent weeks, a multisystem hyperinflammatory condition has emerged in children in association wit
Case abstraction study period was from 10 March to 7 April 2020. Follow-up of abstracted cases was until 7 May 2020.

Case abstraction study period was from 10 March to 7 April 2020. Follow-up of abstracted cases was until 7 May 2020. Courtesy of Nature Medicine

News | Coronavirus (COVID-19) | June 25, 2020
June 25, 2020 — The characterization of COVID-19
Neurosurgeon Jason Sheehan, M.D., Ph.D., of UVA Health, is pioneering the use of focused ultrasound to treat glioblastoma, the deadliest brain tumor. Image courtesy of UVA Health

Neurosurgeon Jason Sheehan, M.D., Ph.D., of UVA Health, is pioneering the use of focused ultrasound to treat glioblastoma, the deadliest brain tumor. Image courtesy of UVA Health

News | Focused Ultrasound Therapy | June 23, 2020
June 23, 2020 — An innovativ...